GABA
Gamma-Aminobutyric Acid
The brain's primary inhibitory neurotransmitter, taken as a supplement to promote relaxation and reduce anxiety.
GABA is the main inhibitory neurotransmitter in the brain, responsible for reducing neuronal excitability. While oral GABA's ability to cross the blood-brain barrier is debated, many users report subjective calming effects. It may work through the gut-brain axis or peripheral receptors. Best used for acute anxiety or sleep support.
Mechanisms of Action
GABA Receptor Activation
May activate GABA receptors, promoting calm
Gut-Brain Communication
May signal relaxation through the gut
Recommended Dose
250-750mg
Optimal Timing
- 30-60 minutes before desired effect
- Before bed for sleep
- Before stressful events for anxiety
Can be taken without food
Best Form
Capsules or powder
Alternatives: Chewables, Sublingual tablets, PharmaGABA (fermented form)
PharmaGABA is a naturally-produced form that may have better effects. Sublingual may work faster.
Duration
Minimum: 1 days
Optimal: days
Cycling: Best used as needed rather than daily. Tolerance may develop with chronic use.
Note: Can be taken with or without food. Start with lower doses to assess response. Some take sublingually for faster effects.
Personalized Dosage Calculator
Get a dosage recommendation tailored to your body weight, age, goals, and health profile.
Set up your health profile for personalized recommendations
Relaxation
Feeling of calm and reduced tension
Reduced Anxiety
Less acute stress and worry
Drowsiness
May cause sleepiness, especially at higher doses
Insufficient data; avoid to be safe
Consult doctor before use
Who Should NOT Take This
- Those taking sedatives or anti-anxiety medications (without doctor approval)
Drug Interactions
May have additive sedative effects
Additive sedative effects
GABA may lower blood pressure
Possible Side Effects
Tip: Reduce dose; don't drive after taking
Tip: Usually harmless and temporary
Tip: Reduce dose significantly
Warnings
- May cause drowsiness — don't drive or operate machinery
- Scientific debate exists about whether oral GABA crosses blood-brain barrier
- Avoid combining with alcohol or sedatives
Top studies from 40+ peer-reviewed papers
Liu J et al. • The Cochrane database of systematic reviews (2018)
“This review provides moderate-quality evidence that fails to support the use of GABA receptor agonists (chlormethiazole or diazepam) for the treatment of people with acute stroke.”
Key Findings:
- The most frequent adverse events related to chlormethiazole were somnolence (RR 4.56, 95% CI 3.50 to 5.95; two trials; 2527 participants; moderate-quality evidence) and rhinitis (RR 4.75, 95% CI 2.67 to 8.46; two trials; 2527 participants; moderate-quality evidence).
- This review provides moderate-quality evidence that fails to support the use of GABA receptor agonists (chlormethiazole or diazepam) for the treatment of people with acute stroke.
- More well-designed RCTs with large samples of participants with total anterior circulation syndrome are required to determine if there are benefits for this subgroup.
- Somnolence and rhinitis are frequent adverse events related to chlormethiazole.
Guo X et al. • JAMA network open (2024)
“Forty- and eighty-mg/d doses of HSK16149 were recommended for treating patients with DPNP in China.”
Key Findings:
- Of 725 randomized patients in the full-analysis set (393 men [54.2%]; mean [SD] age, 58.80 [9.53] years; 700 [96.6%] of Han Chinese ethnicity), 177 received placebo; 178, HSK16149, 40 mg/d; 179, HSK16149, 80 mg/d; 66, HSK16149, 120 mg/d; 63, HSK16149, 160 mg/d; and 62, pregabalin, 300 mg/d.
- A total of 644 patients (88.8%) completed the study.
- In a safety set (n = 726), 545 patients (75.1%) had adverse events, which were generally mild to moderate, with dizziness and somnolence being the most common.
Thomson AR et al. • Neuroscience and biobehavioral reviews (2024)
“All rights reserved.”
Key Findings:
- Data were extracted and grouped by metabolite, brain region and several other factors before calculation of standardised effect sizes.
- Further analysis found these alterations are most pronounced in autistic children and in limbic brain regions relevant to autism phenotypes.
- Additionally, we show how study outcome varies due to demographic and methodological factors , emphasising the importance of conforming with standardised consensus study designs and transparent reporting.Copyright © 2024 The Authors.
- Published by Elsevier Ltd..
Nakahara T et al. • Molecular psychiatry (2022)
“Increased glutamatergic metabolite levels and reduced GABA levels indicate that the disruption of excitatory/inhibitory balance may be related to the pathophysiology of schizophrenia-spectrum disorders.”
Key Findings:
- In the whole group, Glx levels in the basal ganglia (g = 0.32; 95% CIs: 0.18-0.45) were elevated.
- Subgroup analyses showed elevated Glx levels in the hippocampus (g = 0.47; 95% CIs: 0.21-0.73) and dorsolateral prefrontal cortex (g = 0.25; 95% CIs: 0.05-0.44) in unmedicated patients than HC.
- GABA levels in the MCC were decreased in the first-episode psychosis group compared with HC (g = -0.40; 95% CIs: -0.62 to -0.17).
Deligiannidis KM et al. • JAMA psychiatry (2021)
“In this randomized clinical trial, zuranolone improved the core symptoms of depression as measured by HAMD-17 scores in women with PPD and was generally well tolerated, supporting further development of zuranolone in the treatment of PPD.”
Key Findings:
- Of 153 randomized patients, the efficacy set comprised 150 patients (mean [SD] age, 28.3 [5.4] years), and 148 (98.7%) completed treatment.
- Zuranolone demonstrated significant day 15 HAMD-17 score improvements from baseline vs placebo (-17.8 vs -13.6; difference, -4.2; 95% CI, -6.9 to -1.5; P = .003).
- Sustained differences in HAMD-17 scores favoring zuranolone were observed from day 3 (difference, -2.7; 95% CI, -5.1 to -0.3; P = .03) through day 45 (difference, -4.1; 95% CI, -6.7 to -1.4; P = .003).
Study Type Distribution
Goals This Supplement Supports
Related Goals
This information is for educational purposes only and is not intended as medical advice. Always consult a qualified healthcare provider before starting any supplement.